[0001] This invention relates to the semi-synthesis of taxol using a protected baccatin
III backbone which is esterified with a suitably protected side chain acid to produce
an intermediate that may thereafter be acylated and deprotected to produce paclitaxel.
[0002] The chemical compound referred to in the literature as taxol, and more recently "paclitaxel",
has been approved for the chemotherapeutic treatment of several different varieties
of tumors, and the clinical trials indicate that paclitaxel promises a broad range
of potent anti-leukemic and tumor-inhibiting activity. Paclitaxel is a naturally occurring
taxane diterpenoid having the formula:

[0003] While the paclitaxel molecule is found in several species of yew (genus
Taxus, family Taxaceae), the concentration of this compound is very low. The paclitaxel
compound, of course, is built upon the baccatin III backbone, and there are a variety
of other taxane compounds, such as baccatin III, cephalomanine, 10-deacetylbaccatin
III, etc., some which are more readily extracted in higher yields from the yew tree.
[0004] Organic chemists have spent substantial time and resources in attempting to synthesize
the paclitaxel molecule. Partial synthesis of paclitaxel requires convenient access
to chiral, non-racemic side chain and derivatives, an abundant natural source of baccatin
III or closely related diterpenoid substances, and an effective means of joining the
two. Esterification of these two units is difficult because of the hindered C-13 hydroxyl
of baccatin III located within the concave region of the hemispherical taxane skeleton.
For example, Greene and Gueritte-Voegelein reported only a 50% conversion after 100
hours in one partial synthesis of paclitaxel.
J. Am. Chem. Soc., 1988,
110, 5917.
[0005] A promising route to the creation of significant quantities of the paclitaxel compound
has been proposed by the semi-synthesis of paclitaxel by the attachment of the A-ring
side chain to the C-13 position of the naturally occurring baccatin III backbone derived
from the various taxanes present in the yew. See, Denis et al, a "Highly Efficient,
Practical Approach to Natural Taxol", Journal of the American Chemical Society, page
5917 (1988). In this article, the partial synthesis of paclitaxel from 10-deacetylbaccatin
III is described.
[0006] US Patent No 4,929,011 discloses the semi-synthesis of paclitaxel from the condensation
of a (2R, 3S) side chain acid (protected with a hydroxyprotecting group at C2') with
a taxane baccatin III (protected at C7 with a hydroxy protecting group). The condensation
product is subsequently processed to remove the hydroxy protecting groups. The hydroxy
protecting group on the baccatin III backbone is, for example, a trimethylsilyl or
a trialkylsilyl radical.
[0007] An alternative semi-synthesis of paclitaxel is described in co-pending United States
Patent Application S.N. 08/357,507 (corresponding to PCT Application No WO 94/18186).
This application discloses semi-synthesis of paclitaxel from a baccatin III backbone
by the condensation with a different side chain where the C3' nitrogen is protected
as a carbamate. Preferably, the A-ring side chain is benzyloxycarbonyl (CBZ) protected.
After esterification, the CBZ protecting group is removed and replaced by PhCO to
lead to paclitaxel. This process generated higher yields than that described in US
Patent 4,929,011. In the second of the above-cited patent publications, namely PCT
Application No WO 94/18186, the preferred masking groups were selected to be trichloroethoxymethyl
or trichloroethoxycarbonyl. Benzyloxymethyl (BOM) was, however, disclosed as a possible
side chain hydroxyl protecting group for the 3-phenylisoserine side chain, but, according
to the processes described therein, the BOM protecting group could not be removed
from the more encumbered C-2' hydroxyl in the attached 3-phenylisoserine side chain.
The use of the BOM protected side chain was not extensively investigated, for this
reason.
[0008] United States Patent No 4,924,012, issued May 8, 1990 to Colin et al discloses a
process for preparing derivatives of baccatin III and of 10-deacetylbaccatin III,
by condensation of an acid with a derivative of a baccatin III or of 10-deacetylbaccatin
III, with the subsequent removal of protecting groups by hydrogen. Several syntheses
of TAXOTERE (Registered to Rhone-Poulenc Sante) and related compounds have been reported
in the Journal of Organic Chemistry: 1986, 51, 46; 1990, 55, 1957; 1991, 56, 1681;
1991, 56, 6939; 1992, 57, 4320; 1992, 57, 6387; and 993, 58, 255; also, US Patent
No 5,015,744 issued May 14, 1991 to Holton describes such a synthesis.
[0009] Tetrahedron Letters, Volume 35, No 43 (Johnson et al), pages 7893-7896 discloses
7-O-triflates as precursors to olefins and cyclopropanes. According to the authors,
baccatin III-7-0-triflate is coupled with a (4S, 5R)-N-CBZ-2-(2,4-dimethoxyphenyl)-4-phenyl-5-oxazolidinecarboxylic
acid. The resulting product is then transformed through various intermediates. Although
these are taxane analogues, they all have a B-ring without C7-hydroxy protection and
an A-ring without hydrogenatable benzyl protecting group protection at position C2'.
[0010] It is an object of the present invention to provide a new, useful and efficient protocol
for the attachment of a protected A-ring side chain paclitaxel precursor to a protected
baccatin III skeleton which may then be converted into paclitaxel.
[0011] Another object of the present invention is to provide method of production of various
precursor compounds including a paclitaxel-analog A-ring side chain that can be condensed
with a protect baccatin III backbone which, after a combination of acylation and deprotections,
yields paclitaxel.
[0012] Still a further object of the present invention is to provide an efficient and cost
effective protocol for the semi-synthesis of paclitaxel.
[0013] According to the present invention, an N-CBZ protected C-2' benzyl protected (2R,
3S)-3-phenyl isoserine A-ring side chain is coupled to a C-7 TES protected baccatin
III backbone, after which the coupled condensation product undergoes a variety of
deprotections and acylation to form paclitaxel. According to the present invention,
a process of producing paclitaxel from an intermediate having the general formula:

wherein P
1 is a hydrogenatable benzyl protecting group comprises the steps of deprotecting and
acylating the intermediate compound at the nitrogen position of the A-ring side chain
to replace the CBZ protecting group with PhCO. Next, the process includes deprotecting
the C-7 TES baccatin III backbone at C-7 to replace the TES protecting group with
hydrogen and deprotecting the side chain at the C-2' position to replace P
1 with hydrogen. This process includes the step of condensing the N-CBZ protected C-2'
benzyl protected (2R,3S)-3-phenyl isoserine side chain with the C-7 TES protected
baccatin III taxane to produce the intermediate and thereafter conducting the deprotections
and acylation.
[0014] Preferably, the deprotection at the C-7 site to remove the TES protecting group occurs
before the removal of the hydrogenatable C-2' benzyl protecting group. Here, the step
of deprotecting and acylating the side chain nitrogen occurs before the step of deprotecting
at C-7 to remove the TES protecting group. Alternatively, the deprotecting at the
C-7 site occurs before the step of deprotecting and acylating in the side chain nitrogen.
The step of deprotecting to remove the TES protecting group at C-7 is preferably accomplished
in acetonitrile in the presence of and hydrofluoric acid.
[0015] According to one process described herein, the step of deprotecting and acylating
the side chain at the nitrogen site is accomplished by dissolving the intermediate
compound in isopropanol and thereafter mixing with Pearlman's catalyst under a hydrogen
atmosphere to form a first mixture and thereafter reducing the first mixture to residue,
taking up the residue in a solvent and a tertiary amine base to which benzoyl chloride
is thereafter added. Here the solvent is selected from a group consisting of ethyl
acetate and toluene and the tertiary amine base is preferably triethylamine.
[0016] These and other objects of the present invention will become more readily appreciated
and understood from a consideration of the following detailed description of the exemplary
embodiments.
DETAILED DESCRIPTION OF THE EXEMPLARY EMBODIMENTS
[0017] The present disclosure is broadly directed to a chemical process for the efficient
production of paclitaxel, intermediates and precursors therefor. More specifically
the present invention concerns the semi-synthesis of paclitaxel by esterifying (suitably
protected) 3-phenylisoserine acids having hydrogenatable benzyl protecting groups
at C-2' to the C-13 hydroxyl of 7-0-protected baccatin III. More particularly, the
present invention utilizes triethylsilyl (TES) protection at the C-7 site. The general
process described herein involves the production of C-7 TES baccatin III, the production
of the suitably protected 3-phenylisoserine acid having a hydrogenatable benzyl protecting
group at C-2', the condensation of the two compounds, and the subsequent deprotection
and acylation of the condensation product to form paclitaxel.
A. Production of C-7 TES Protected Baccatin III
[0018] As a starting point in the semi-synthesis of paclitaxel according to the exemplary
embodiment of the present invention, it is necessary to provide the baccatin III backbone
onto which the paclitaxel-analog side chain may be attached. According to the present
invention, it is preferred that this backbone be in the form of the basic baccatin
III backbone that is protected at the C-7 site with a TES protecting group. Particularly,
it is desired to provide a reaction intermediate of the formula:

The compound of formula may hereinafter be referred as TES-protected baccatin III,
and its preparation may be accomplished by the various routes described in the literature.
[0019] One such route is described in Denis et al, "A highly Efficient, Practical Approach
to Natural Taxol,
Journal of the American Chemical Society, p. 5917 (1988). Here, 10-deacetylbaccatin III is first converted to C-7 TES protected
10-deacetylbaccatin III and subsequently the C-7.TES protected 10-deacetylbaccatin
III is converted to C-7 TES protected baccatin III by the acylation of the compound
at the C-10 location. C-7 TES protected 10-deacetylbaccatin III is achieved according
to the following reaction:

Here, 10-deacetylbaccatin III is reacted with a large excess of TES-Cl and pyridine
to produce C-7 TES protected 10-deacetylbaccatin III. The product is next acylated
utilizing an excess of acetyl chloride and pyridine to produce C-7 TES baccatin III.
[0020] Alternatively, C-7 TES protected baccatin III may be efficiently produced according
to the procedure described in Kant et al "A Chemo Selective Approach To Functionalize
the C-10 Position of 10-deacetylbaccatin III Synthesis and Biological Properties of
Novel C-10 Taxol® Analogs",
Tetrahedron Letters, Vol. 35, No. 31, TP5543-5546 (1994). As described in this article, C-7 TES protected
C-10 hydroxy baccatin III may be obtained according to the reaction:

Here, imidazole is added while stirring to a solution of 10-deacetylbaccatin III
in dimethylformamide (DMF) under a nitrogen atmosphere. Triethylsilyl chloride (TES-Cl)
is then added dropwise over a period of approximately five minutes. The resulting
solution is stirred or otherwise moderately agitated for three hours after which the
mixture is quenched with water and extracted with two portions of either diethyl ether
or methyl t-butyl ether, and the combined organics are mixed and washed with four
portions of water and one portion brine. The organic and aqueous layers are then separated
and the organic layer is dried and reduced under vacuum to form a crude solid. This
crude solid is then recrystallized from ethyl acetate/hexane to produce C-10 hydroxy
C-7 TES baccatin III.
[0021] Next, the C-10 hydroxy C-7 TES baccatin III is acylated to produce C-7 TES baccatin
III according to the following reaction:

The C-10 hydroxy C-7 TES baccatin III is dissolved in anhydrous tetrahydrofuran (THF)
and the solution is cooled under a nitrogen atmosphere to a temperature of less than
- 20°C. n-Butyl lithium (1.6M in hexane) is added dropwise, and the mixture is stirred
at the reduced temperature for approximately five minutes. Acetyl chloride is then
added dropwise and the mixture warmed to O°C over an interval of five minutes and
then stirred at that temperature for approximately one hour. The mixture is then quenched
with water and reduced under vacuum, after which the residue is taken up in ethyl
acetate and washed once with water and then brine. The organic layer may then be dried
and reduced under vacuum, and the residue recrystallized with ethyl acetate/hexane
to yield C-7 TES baccatin III as a white solid. The selected electrophile is AcCl.
A yield of 90% was reported in this article.
[0022] Alternatively, of course, the C-7 TES protected baccatin III can be made directly
from baccatin III instead of the route described above for the conversion from 10-deacetylbaccatin
III.
B. Production of N-carbamate Protected C-2' hydroxyl-Benzyl Protected (2R,3S) 3-Phenyl
Isoserine A-ring Side Chain
[0023] The second precursor necessary for the semi-synthesis of paclitaxel according to
the present invention is the N-carbamate protected C-2' hydroxyl-benzyl protected
(2R,3S) phenyl isoserine side chain having the general formula:

wherein R
1 is an alkyl, olefinic, or aromatic PhCH
2 and P
1 is a hydrogenatable benzyl protecting group
The preferred hydrogenatable benzyl protecting group is a benzyloxymethyl (BOM) protecting
group although other hydrogenatable benzyl protecting groups, including benzyl, are
believed suitable as well. The preferred N-carbamate protecting group is benzyloxycarbonyl
(CBZ). The starting compound to produce the desired side chain is (2R,3S)-3-phenylisoserine
ethyl ester to produce N-CBZ protected (2R,3S)-3-phenylisoserine ethyl ester according
to the reaction:

Here, (2R,3S)-3-phenylisoserine ethyl ester was alternatively dissolved in either
equal parts diethyl ether:water or equal parts methyl t-butyl ether:water and the
solution was cooled to O°C. The sodium carbonate was then added to the solution and
benzylchloroformate was added dropwise over an interval of about five minutes and
the resulting mixture stirred at O°C for approximately one hour. After the one hour
stirring, the solution was then poured into water and extracted with methylene chloride
or ethyl acetate, as desired. The organic layer is separated, dried and reduced under
vacuum to residue. The residue was then recrystallized from ethyl acetate:hexane to
result in N-CBZ protected (2R,3S)-3-phenylisoserine ethyl ester having the formula:

[0024] The N-CBZ protected (2R,3S)-3-phenylisoserine ethyl ester was next protected by the
hydrogenatable benzyl protecting group, in several ways. For example, one route to
the desired hydrogenatable benzyl protected side chain is as follows:

Here, the CBZ protected (2R,3S)-3-phenylisoserine ethyl ester is dissolved in anhydrous
THF under a nitrogen atmosphere and cooled to a reduced temperature such as -40°C
or -78°C, for example, in a dry ice/acetone bath followed by the dropwise addition
of an alkylithium agent, such as n-butyl lithium, although it is desirable that the
alkylithium agent be a straight chain alkyl. In any event, the reaction is best done
at a temperature no greater than 0°C. The resulting mixture was stirred for about
ten minutes. Benzyloxymethyl chloride (BOM-Cl) was then added dropwise over an interval
of about five minutes and the mixture stirred for approximately two to five hours
at the reduced temperature. Thereafter, the solution was warmed to -0°C and quenched
with water. The resulting mixture is reduced under vacuum to residue, and this residue
is thereafter taken up in ethyl acetate and washed with water and brine. The organic
layer may then be dried and reduced under vacuum and the residue recrystallized from
ethyl acetate:hexane or chromotographed with ethyl acetate:hexane to give the compound:

[0025] Another route in the production of the compound according to formula 5 is accomplished
by dissolving the compound N-CBZ (2R,3S)-3-phenylisoserine ethyl ester in anhydrous
methylene chloride. Thereafter, a tertiary amine base, such as diisopropylethylamine,
is added along with BOM-C1 and the mix is refluxed for twenty-four hours. While this
reaction route will produce N-CBZ protected C-2' [hydroxyl] protected (2R,3S)-3-phenylisoserine
ethyl ester, the reaction proceeds much slower than the preferred route, discussed
above.
[0026] In either instance, the resulting protected (2R,3S)-3-phenylisoserine ethyl ester
compound of formula 5 may simply be converted to the N-CBZ protected C-2' O-BOM-protected
(2R,3S) phenylisoserine intermediate hydroxyl by the reaction:

[0027] Here, the protected (2R,3S)-3-phenylisoserine ethyl ester is dissolved in ethanol/water
(ratio 8:1). Lithium hydroxide (or other suitable alkali hydroxide) is added to the
solution and the resulting mixture stirred for approximately three hours in order
to saponify the compound. The mixture is then acidified (1N HC1) and extracted with
ethyl acetate. The resulting organic layer is separated, dried and reduced under vacuum.
The residue acid is then isolated for use without further purification. This produces
the desired side chain having the general formula:

[0028] Benzyl itself is another example of a hydrogenatable benzyl protecting group that
may be used instead of BOM. The compound of the formula:

was therefore produced as above with the substitution of benzyl bromide for BOM-Cl
in Reaction V according to the reaction

Here, the CBZ protected (2R,3S)-3-phenylisoserine ethyl ester is dissolved in anhydrous
THF under a nitrogen atmosphere and cooled to a reduced temperature such as -40°C
or -78°C, for example, in a dry ice/acetone bath followed by the dropwise addition
of an alkylithium agent, such as n-butyl lithium, although it is desirable that the
alkylithium agent be a straight chain alkyl. The resulting mixture was stirred for
about ten minutes. Benzyl bromide (BnBr) was then added dropwise over an interval
of about five minutes and the mixture stirred for approximately two to five hours
at the reduced temperature. Thereafter, the solution was warmed to-0°C and quenched
with water. The resulting mixture is reduced under vacuum to residue, and this residue
is thereafter taken up in ethyl acetate and washed with water and brine. The organic
layer may then be dried and reduced under vacuum and the residue recrystallized from
ethyl acetate:hexane or chromatographed with ethyl acetate:hexane to give the compound
of Formula 10.
[0029] Alternatively, the compound of Formula 7 may be obtained according to the reaction:

Here, to a stirred solution of NaH in anhydrous DMF under N
2 was added Formula 4 dissolved in DMF over five minutes. The mixture was then stirred
at O°C for one half hour. After which time benzyl bromide (1.1 equivalents) was added
dropwise over five minutes and the reaction stirred for two hours. The mixture was
then quenched with H
2O. Thereafter, a selected one of diethylether and methyl t-butyl was added. The organic
layer was then washed with four portions of H
2O, brine, and then dried and reduced under vacuum to produce Formula 10. Formula 7
may then be readily converted into:

by the process of Reaction VI, above.
C. Condensation of C-7 TES Protected Baccatin III and the Side Chain
[0030] The side chain designated above as Formula 6 (or Formula 8) as well as the C-7 TES
protected baccatin III may now be condensed, again by a variety of routes. By way
of example, this condensation may proceed in the presence of a diisopropylcarbodiimide
and dimethylamino pyridine (DMAP) in toluene at 80°C according to the reaction:

Here, C-7 TES protected baccatin III (1 equivalent) and the acid side chain of Formula
9 (6 equivalents) are dissolved in toluene. To this mixture DMAP (2 equivalents) and
diisopropylcarbodiimide (6 equivalents) are added, and the resulting mixture heated
at 80°C for three to five hours. It should be noted, however, that other dialkyl carbodiimides
may be substituted for the diisopropylcarbodiimide, with one example being dicyclohexylcarbodiimide
(DCC). Next, the solution was cooled to O°C and held at this temperature for twenty-four
hours. After this time it was filtered and the residue rinsed with either ethyl ether
or methyl t-butyl ether. The combined organics were then washed with hydrochloric
acid (5%), water and, finally, brine. The organic phase was separated, dried and reduced
under vacuum. The resulting residue was then dissolved in ethyl acetate:hexane and
eluted over a silica gel plug. The eluent is then reduced under vacuum to result in
the compound:

D. Deprotections and Acylation to Form Paclitaxel
[0031] The compound according to the Formula 9 may now be converted into paclitaxel by removing
the CBZ protecting group and acylating the side chain, removing the TES protecting
group and removing the hydrogenatable benzyl protecting group. Here, several convenient
routes have been found although in general, it is necessary to deprotect the C-7 site
by removing the TES protecting group prior to deprotecting the C-2' site with the
hydrogenatable benzyl protecting group. If the TES protecting group is not removed
first, it is believed difficult at best to remove the hydrogenatable protecting group
in a later processing step.
[0032] In any event, the preferred route of producing paclitaxel is to first remove the
CBZ protecting group according to the reaction:

Here, the coupled product of Formula 9 is dissolved in isopropanol to which the Pearlman's
catalyst is added. The resulting mixture is stirred under one atmosphere of hydrogen
for twenty-four hours. Thereafter, the mixture is filtered through diatomaceous earth
and reduced under vacuum to residue. The residue may then be taken up in ethyl acetate
or toluene and a tertiary amine base, such as triethylamine is added. Benzoyl chloride
was added dropwise, and the mixture stirred for two hours. The resulting mixture was
then washed with dilute NaHCO
3, water, and finally brine. The resulting organic phase was then separated, dried
and reduced under vacuum to yield the CBZ deprotected/acylated compound:

[0033] Next, the compound of Formula 10 is deprotected at C-7 according to the reaction:

Here, the compound of Formula 10 was dissolved in acetonitrile (CH
3CN) at 0°C. Hydrofluoric acid (40% aqueous) was then added and the mixture stirred
for ten hours while being held at 0°C. Thereafter, the mixture is diluted with ethyl
acetate, saturated NaHCO
3, water and finally brine. The organic phase was separated, dried and reduced under
vacuum to produce a deprotected product at the C-7 position according to the formula:

[0034] Finally, the compound of Formula 11 is deprotected at C-2' to remove the hydrogenatable
benzyl (BOM) protecting group and to liberate the C-2' hydroxy group thereby resulting
in the desired paclitaxel. This is accomplished according to the reaction:

[0035] Alternatively, the compound of Formula 9 may first be dissolved in CH
3CN at 0°C and hydrofluoric acid (40% aqueous) added to deprotect the compound at the
C-7 site by removing the TES protecting group. This results in a compound according
to the formula:

Next, the CBZ protecting group may be removed in a manner similar to that described
above. Here, the compound of Formula 15 is dissolved in isopropanol and Pearlman's
catalyst was added along with trifluoroacetic acid (TFA) (1 equivalent). The mixture
was held at 40 psi of hydrogen at room temperature for approximately four days. This
removes the CBZ protecting group and forms the C-2' BOM protected paclitaxel compound
as a TFA salt. The mixture was filtered through diatomaceous earth and reduced under
vacuum. Next, a base plus an acylating agent was added to the residue. Specifically,
the TFA salt of the C-2' BOM protected compound was dissolved in pyridine and either
benzoyl chloride or benzoic anhydride was added. The resulting product is:

[0036] The compound of Formula 13 is dissolved in isopropyl alcohol and placed in a Parr
bottle and Pearlman's catalyst was added. The mixture was hydrogenated for twenty-four
hours at 40 psi of hydrogen. Thereafter, the mixture was filtered through diatomaceous
earth and the eluent reduced under vacuum. The residue may then be column chromatographed
according to any desired technique or recrystallized from ethyl acetate:hexane for
the final paclitaxel product.